|
In
memoriam 1950 Before
joining the University of Washington faculty, he was a postdoc at the
National Institutes of Health (1956), an assistant professor at the University
of Wisconsin Medical School (1957-61), and an associate professor at the
University of Texas Medical Branch at Galveston (1961-67). He had two
sons, Jonathan and Eric, and a daughter, Becky. He lived in Edmonds, WA. 1953 A
native New Yorker, he received his B.S. from Brooklyn College and, following
his graduate studies at Cal, did postdoctoral work at MIT and Cambridge
University. In 1956 he joined the faculty at Polytechnic Institute of
Brooklyn, eventually assuming directorship of the school’s Polymer Research
Institute. He left in 1970 to join the faculty of UCSD, where he served
for six years as chair of the chemistry department. 1994 He
earned his B.S. in chemistry at Bates College and did his doctoral work
at Berkeley under the direction of Peter Schultz, in whose laboratory
he developed the first antibodies that catalyzed oxy-Cope rearrangements.
These antibodies later became important for understanding structural changes
that accompany the maturation of antibody catalysis. As
a postdoctoral researcher with James A. Wells at Genentech, he did a series
of studies showing it was possible to make “minimalized” versions of protein
A through a combination of phage display, rational design, and peptide
chemistry. He demonstrated that selection methods evolve function both
by optimizing binding determinants and by folding. In 1998, he became the
first scientist to join Sunesis Pharmaceuticals, founded by Wells, in
South San Francisco. He was an instrumental figure in the company, helping
to build its scientific and technological capabilities, as well as its
staff, facility, and even its name. He was co-inventor of an important
fragment-based drug discovery technology called “tetheringSM,” a highly
sensitive technique that screens fragments rather than full molecules
of drug leads, and he was a central member of a team that developed high-affinity
small-molecule inhibitors to the cytokine interleukin-2. Braisted is survived
by his wife, Joelle Morrow, M.D., and his son, Miles Andrew Braisted. |
|
|
|
|